John A. Roberts Purchases 5,000 Shares of Vyant Bio, Inc. (NASDAQ:VYNT) Stock

Vyant Bio, Inc. (NASDAQ:VYNT) CEO John A. Roberts acquired 5,000 shares of the business’s stock in a transaction on Wednesday, November 24th. The stock was bought at an average cost of $2.02 per share, for a total transaction of $10,100.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ:VYNT traded up $0.06 during mid-day trading on Thursday, hitting $2.05. The company had a trading volume of 62,779 shares, compared to its average volume of 908,424. The business has a fifty day simple moving average of $2.31 and a 200-day simple moving average of $2.89. Vyant Bio, Inc. has a 1 year low of $1.98 and a 1 year high of $17.50.

Vyant Bio (NASDAQ:VYNT) last announced its earnings results on Thursday, November 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.15). Vyant Bio had a negative return on equity of 34.55% and a negative net margin of 254.97%. During the same quarter last year, the business earned ($0.58) EPS. Equities analysts anticipate that Vyant Bio, Inc. will post 0.75 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Vyant Bio by 881.6% during the second quarter. Vanguard Group Inc. now owns 839,226 shares of the company’s stock worth $3,139,000 after acquiring an additional 753,728 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Vyant Bio by 203.0% during the second quarter. Geode Capital Management LLC now owns 176,680 shares of the company’s stock worth $660,000 after acquiring an additional 118,375 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Vyant Bio during the first quarter worth about $182,000. Bank of Montreal Can purchased a new stake in shares of Vyant Bio during the second quarter worth about $37,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Vyant Bio during the second quarter worth about $49,000. 7.75% of the stock is currently owned by institutional investors and hedge funds.

Separately, HC Wainwright assumed coverage on Vyant Bio in a research report on Wednesday, October 6th. They issued a “buy” rating and a $5.00 price objective on the stock.

About Vyant Bio

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

Further Reading: What is dividend yield?

Insider Buying and Selling by Quarter for Vyant Bio (NASDAQ:VYNT)

Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.